Three Months Ended March 31, 2016

Diagnostics

Therapeutics

Corporate

Total

Lymphoseek sales revenue:

United States ⁽¹⁾

$

3,771,420

$

—

$

—

$

3,771,420

International

11,260

—

—

11,260

Lymphoseek license revenue

254,050

—

—

254,050

Grant and other revenue

685,825

—

—

685,825

Total revenue

4,722,555

—

—

4,722,555

Cost of goods sold, excluding depreciation and amortization

494,639

—

—

494,639

Research and development expenses,

   excluding depreciation and amortization

2,417,720

241,800

—

2,659,520

Selling, general and administrative expenses,

   excluding depreciation and amortization ⁽²⁾

1,012,106

(598

)

2,975,850

3,987,358

Depreciation and amortization ⁽³⁾

40,290

—

109,302

149,592

Loss from operations ⁽⁴⁾

757,800

(241,202

)

(3,085,152

)

(2,568,554

)

Other income (expense), excluding

   equity in the loss of R-NAV, LLC ⁽⁵⁾

—

—

(1,105,456

)

(1,105,456

)

Equity in the loss of R-NAV, LLC

—

—

(12,239

)

(12,239

)

Net loss

757,800

(241,202

)

(4,202,847

)

(3,686,249

)

Total assets, net of depreciation and amortization:

United States

4,109,640

16,515

7,774,939

11,901,094

International

380,982

—

1,605

382,587

Capital expenditures

—

—

1,847

1,847

Three Months Ended March 31, 2015

Diagnostics

Therapeutics

Corporate

Total

Lymphoseek sales revenue:

United States ⁽¹⁾

$

1,831,022

$

—

$

—

$

1,831,022

International

4,400

—

—

4,400

Lymphoseek license revenue

83,333

—

—

83,333

Grant and other revenue

189,701

—

—

189,701

Total revenue

2,108,456

—

—

2,108,456

Cost of goods sold, excluding depreciation and amortization

420,551

—

—

420,551

Research and development expenses,

   excluding depreciation and amortization

3,890,724

86,014

—

3,976,738

Selling, general and administrative expenses,

   excluding depreciation and amortization ⁽²⁾

2,042,175

14,366

3,320,861

5,377,402

Depreciation and amortization ⁽³⁾

33,056

—

116,766

149,822

Loss from operations ⁽⁴⁾

(4,278,050

)

(100,380

)

(3,437,627

)

(7,816,057

)

Other income (expense), excluding

   equity in the loss of R-NAV, LLC ⁽⁵⁾

—

—

787,059

787,059

Equity in the loss of R-NAV, LLC

—

—

(262,227

)

(262,227

)

Net loss

(4,278,050

)

(100,380

)

(2,912,795

)

(7,291,225

)

Total assets, net of depreciation and amortization:

United States

3,333,851

7,409

7,077,673

10,418,933

International

496,311

—

2,665

498,976

Capital expenditures

—

—

—

—

⁽¹⁾

All sales to Cardinal Health are made in the United States; Cardinal distributes the product throughout the U.S. through its network of nuclear pharmacies.

⁽²⁾

General and administrative expenses, excluding depreciation and amortization, represent costs that relate to the general administration of the Company and as such are not currently allocated to our individual reportable segments.  Marketing and selling expenses are allocated to our individual reportable segments.

⁽³⁾

Depreciation and amortization is reflected in cost of goods sold ($40,290 and $28,506 for the three-month periods ended March 31, 2016 and 2015), research and development ($0 and $4,550 for the three-month periods ended March 31, 2016 and 2015), and selling, general and administrative expenses ($109,302 and $116,765 for the three-month periods ended March 31, 2016 and 2015).

⁽⁴⁾

Loss from operations does not reflect the allocation of certain selling, general and administrative expenses, excluding depreciation and amortization, to our individual reportable segments.

⁽⁵⁾

Amounts consist primarily of interest income, interest expense, changes in fair value of financial instruments, and losses on debt extinguishment, which are not currently allocated to our individual reportable segments.